Compare ADMA Biologics Inc (ADMA) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Tenet Healthcare Corporation — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Tenet Healthcare Corporation trades at $206.47 (market cap $17.76B). The key difference: Tenet Healthcare Corporation is far larger — about 8.3× ADMA Biologics Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | THC | |
|---|---|---|
Market Cap | $2.13B | $17.76B |
Sector | Health | Health |
52-Week High | $20.38 | $244.80 |
52-Week Low | $7.60 | $148.38 |
Enterprise Value | $2.20B | $28.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Tenet Healthcare (THC) trades at $206.19, up 1.21% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The stock shows robust fundamentals with a P/E of 10.72, net income margin of 7.79%, and consistent earnings beats in recent quarters. Recent news highlights growth in outpatient care and positive market performance amid broader dips.
Outlook remains positive with an 81.25% analyst buy rating and $233.38 consensus price target, though overbought RSI signals near-term caution. Risks include healthcare regulatory pressures and debt levels, but expanding admissions and solid cash flow support long-term upside for value and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
